Luminous red nova

Women Deemed Inoperable for Breast Cancer Benefitted from IceCure Medical's ProSense as an Independent Study Performed in Italy Showed a Tumor Reduction Rate of 93.43% to 96.81%

Retrieved on: 
Thursday, October 5, 2023
Neoplasm, Breast cancer, Breast, ICE3, Safety, Luminous red nova, Freezing, Luminal, Biopsy, Patient, Principal investigator, European Society of Radiology, PMID, Woman, Medical imaging

This independent study adds to the growing body of scientific data using ProSense in women deemed inoperable for breast cancer.

Key Points: 
  • This independent study adds to the growing body of scientific data using ProSense in women deemed inoperable for breast cancer.
  • During the study, ultrasound-guided cryoablation using ProSense was performed on 28 women, who had biopsy-proven malignant lesions, and were deemed inoperable by a multidisciplinary group, and submitted to hormone therapy.
  • At a median age of 73.4 years, 14 of the women were diagnosed with molecular subtype Luminal-A tumors and another 14 diagnosed with Luminal-B tumors.
  • Patients were monitored at one, three, and six months post-procedure, at which time the tumor size reduction rate was evaluated by ultrasound.